Clinical Trial Update: Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated cisplatin, irinotecan, and bevacizumab in patients with extensive-stage small cell lung cancer; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CISPLATIN (cisplatin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extensive Stage Small Cell Lung Cancer | Phase 2 | Status: COMPLETED